BioCentury
ARTICLE | Company News

Teva names new CEO after seven-month hunt

September 11, 2017 11:19 PM UTC

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) jumped on Monday after naming Kåre Schultz president and CEO. Teva gained $3 (19%) to $18.50 in New York and NIS9.06 (17%) to NIS63.55 in Tel Aviv.

Teva has been seeking a new CEO since Erez Vigodman resigned in February. It also continues to search for a new CFO since Eyal Desheh announced his resignation in April (see BioCentury Extra, Feb. 6 & April 26)...